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Letter to the EditorIdentiﬁcation of a novel deletion in UDP-glucuronosyltransferase
gene in a patient with Crigler–Najjar syndrome type IDear Editor:
Unconjugated bilirubin (UCB) is formed by the catabolism of heme
and owing to its very low water solubility (b70 nM), over 99.9% is
tightly bound to albumin. During hyperbilirubinemia, slightly elevated
unbound concentrations may become neurotoxic, if UCB hepatic
clearance is impaired. After uptake by the liver, UCB is conjugatedwith
either one or two molecules of glucuronic acid converting UCB in
water soluble compounds [1]. Hepatic glucuronidation of bilirubin is
catalyzed by isoenzyme 1A1 of uridine 5′-diphosphate-(UDP)-
glucuronosyltransferase (UGT1A1), which is essential for its efﬁcient
biliary excretion. Genetic alterations causing absence, or severe
reduction, of UGT1A1 enzymatic activity result respectively in
Crigler–Najjar syndrome (CNS) type I and type II [1,2]. CNS types I
and II (MIM #218800 and MIM #606785) can be differentiated by the
bile proﬁle of bilirubin species and by evaluating the response to
phenobarbital treatment or other enzyme-inducing agents [2]. CNS
type I patients have higher UCB and lower percentages of bilirubin
monoglucuronide (MGB) and diglucuronide (DGB) in bile than is the
case CNS type II (CNS type I: 91±10% UCB, 9±11% MGB and 1±1%
DGB; CNS type II: 37±9% UCB, 56±13% MGB and 8±5% DGB) [3]. In
addition, serum bilirubin levels in patients with CNS type II can be
lowered by phenobarbital treatment while CNS type I hyperbilirubi-
nemia is unresponsive to that therapy [2]. Diagnosis of CNS type I
patients is of major relevance because at the present time, liver
transplantation is the sole curative treatment.
The UGT1A1 enzyme is encoded by ﬁve exons located at the 3′ end
of the UGT1A locus and is expressed mainly in the liver, and to a lesser
extent in the biliary tract, duodenum and colon. The ﬁrst mutation
described in this gene, in 1992 [4], was a nonsense mutation found in
homozygosity in a patient with CNS type I. To date, more than 90
mutations causing CNS have been identiﬁed, most of which are
missense or nonsense mutations [5]. The phenotypes of CNS types I
and II are usually associated with homozygosity or compound
heterozygosity for nonsense and/or missense mutations. A combina-
tion of point mutations and abnormal TA repeat numbers in the
promoter region of the UGT1A1 gene has also been described in these
forms. This TA duplication in the repetitive TATA-box sequence of the
gene promoter, which normally consists of six TA repeats, was found
to be the main cause of Gilbert syndrome (associated with a small
reduction in UGT1A1 enzymatic activity) in all reports based on
population studies. Deletions in the UGT1A1 gene are rarely described
in the literature [5].
We report the molecular characterization of a Portuguese patient
presenting clinical and biochemical features of CNS type I since
neonatal period.
The infant was born at full term after an uneventful pregnancy, by
eutocic delivery, weighing 3360 g, from non-consanguineous parents
and without family history of jaundice. Serum total bilirubin was15 mg/dL on the second day of life. The child was exposed to intensive
phototherapy on the 15th day, when she presented 28.8 mg/dL of
serum total bilirubin and 0.8 mg/dL of serum conjugated bilirubin,
attesting that the unconjugated species was the predominant one.
At 5 weeks of age, total/conjugated bilirubin in serum was 34.7/
0.9 mg/dL (maximal detected value). Enzymatic induction by
phenobarbital (20 mg/kg followed by daily administration of 5 mg/
kg) was inefﬁcient in signiﬁcantly reducing the serum UCB concen-
tration. To better characterize the patient, and since determination of
hepatic glucuronyl transferase does not differentiate CNS type I and
type II patients, determination of the bile proﬁle of bilirubin species
was performed. The relative amounts of biliary UCB and bilirubin
conjugates were measured by alkaline methanolysis followed by thin-
layer chromatography [6] and expressed as % of total bilirubin. We
found 90% of UCB, 6% MGB and 4% DGB supporting the diagnosis of
CNS type I, despite the slight elevation in DGB percentage when
compared with the reported values for CNS type I patients.
Thus, after informed consent, genetic analysis of the patient and the
parents was performed as previously described [7]. Sequencing of the
ﬁve exons of theUGT1A1 gene from the patient revealed the presence of
a novel 24 bp deletion (c.609_632del) encompassing theﬁrst exon. Both
parents were found to be carriers, thereby conﬁrming homozygosity in
the patient (Fig. 1). Screening for the TA duplication in the promoter
region of UGT1A1 showed a normal number of repeats in the patient
and in her parents. None of the three presented the c.-3279TNG
polymorphism in the phenobarbital-responsive enhancer module of
UGT1A1 gene, known to be associated with Gilbert syndrome.
This novel gross c.609_632del mutation predictably gives rise to an
internally deletedpolypeptide (p.His203_Lys211delinsGln). Thedeletion
is located in exon 1, encoding the substrate speciﬁc region of bilirubin-
UDP-glucuronosyltransferase may result in an unstructured protein [8].
The patient has been treated with daily phototherapy (NeoBLUE®)
and ursodesoxycholic acid (15 mg/kg/day) and the value of the last
serumtotal bilirubin concentrationwas10.6mg/dL. The child is presently
2 years old and does not reveal any psychomotor or neurological
impairment. Nevertheless, since kernicterus may suddenly develop,
liver transplantation should be considered as a therapeutic option.
Additionally to extend our knowledge of the spectrum of disease
variants, the identiﬁcation of this deletion in exon 1 of the UGT1A1
gene may contribute towards a better understanding of the molecular
pathology of the disorders characterized by severe unconjugated
hyperbilirubinemia, and potentially be used as an antenatal screening
tool to identify the affected offspring.References
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Fig. 1. Novel homozygous mutation in exon 1 of the UGT1A1 gene (c.609_632del) found in a Portuguese patient with Crigler–Najjar type I. (A) Family pedigree. (B) Sequence analysis
revealing homozygosity in the patient and heterozygosity in the mother for the 24 bp deletion (c.609_632delCATGACCTTCCTGCAGCGGGTGAA).
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